An analysis of Jim Cramer's underperforming stocks includes DexCom, Inc. struggling due to competition, pricing pressures, and potential decline in demand for continuous glucose monitoring devices amid advancements in diabetes treatments. The company's stock dropped post lower sales projections and revised revenue forecasts.